Skip to main content
. 2023 Apr 12;109(5):1330–1341. doi: 10.1097/JS9.0000000000000370

Figure 2.

Figure 2

Relationship between HER2 status and benefit from adjuvant chemotherapy. (A) Stage II subgroup with low HER2 expression [immunohistochemistry (IHC) scores of 0/1+]; (B) stage III subgroup with low HER2 expression; (C) stage II subgroup with high HER2 expression (IHC scores of 2/3+); (D) stage III subgroup with high HER2 expression; (E) treatment interaction with HER2 expression for 5-year overall survival. HER2, human epidermal growth factor receptor 2; HR, hazard ratio.